Compare · AVR vs STE
AVR vs STE
Side-by-side comparison of Anteris Technologies Global Corp. (AVR) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVR and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.73B, about 22.1x AVR ($938.4M).
- Over the past year, AVR is up 73.8% and STE is down 13.2% - AVR leads by 86.9 points.
- STE has been more active in the news (32 items in the past 4 weeks vs 7 for AVR).
- STE has more recent analyst coverage (16 ratings vs 6 for AVR).
- Company
- Anteris Technologies Global Corp.
- STERIS plc (Ireland)
- Price
- $9.38-2.75%
- $210.79-0.66%
- Market cap
- $938.4M
- $20.73B
- 1M return
- +44.01%
- -1.52%
- 1Y return
- +73.77%
- -13.17%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 7
- 32
- Recent ratings
- 6
- 16
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest AVR
- Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance
- Director Knight Susan Elizabeth bought $102,228 worth of shares (11,000 units at $9.29) (SEC Form 4)
- SEC Form 424B3 filed by Anteris Technologies Global Corp.
- Anteris Technologies Global Corp. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form 424B5 filed by Anteris Technologies Global Corp.
- SEC Form 3 filed by new insider Knight Susan Elizabeth
- New insider Denaro Stephen claimed ownership of 23,722 shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Anteris Technologies Global Corp.
- Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors
- Anteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 184 units of Ordinary Shares, decreasing direct ownership by 2% to 11,482 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 311 units of Ordinary Shares, decreasing direct ownership by 2% to 14,316 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 2,619 units of Ordinary Shares, decreasing direct ownership by 4% to 69,964 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 190 units of Ordinary Shares, decreasing direct ownership by 1% to 13,274 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam was granted 4,359 units of Ordinary Shares and covered exercise/tax liability with 247 units of Ordinary Shares, increasing direct ownership by 12% to 37,444 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato was granted 750 units of Ordinary Shares and covered exercise/tax liability with 41 units of Ordinary Shares, increasing direct ownership by 13% to 6,323 units (SEC Form 4)